Literature DB >> 7962990

Beta-lactamases: current situation and clinical importance.

J Garau1.   

Abstract

Production of beta-lactamases is the most important means of bacterial resistance to beta-lactam antibiotics. The traditional, plasmid-mediated beta-lactamases were initially confined to Enterobacteriaceae but have now spread to other genera and species including Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. Extended-spectrum plasmid-mediated beta-lactamases have been identified in Enterobacteriaceae, particularly Klebsiella spp. and Escherichia coli. They are capable of hydrolyzing second- and third-generation cephalosporins and older beta-lactams. Chromosomally mediated beta-lactamases may be produced constitutively or induced by the presence of a beta-lactam. Mutation within the bacterial genome may lead to constitutive enzyme hyperproduction. Strains that produce these enzymes are resistant to practically all beta-lactams, with the exception of carbapenems. The wide-spread occurrence of antibiotic resistance dictates that therapies be judiciously chosen with attention to the resistance patterns of the causative organisms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962990     DOI: 10.1007/BF01745244

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  21 in total

Review 1.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 2.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 3.  Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins.

Authors:  W E Sanders; C C Sanders
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 4.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Clinical consequences of development of resistance to third generation cephalosporins.

Authors:  F Follath; E Costa; A Thommen; R Frei; A Burdeska; J Meyer
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

6.  Ceftazidime in the treatment of serious Pseudomonas aeruginosa sepsis.

Authors:  S Bragman; R Sage; L Booth; P Noone
Journal:  Scand J Infect Dis       Date:  1986

7.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

8.  Transferable imipenem resistance in Pseudomonas aeruginosa.

Authors:  M Watanabe; S Iyobe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

9.  Moxalactam in nosocomial infections with Serratia marcescens.

Authors:  T Mall; F Follath; M Salfinger; R Ritz; H Reber
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

10.  Moxalactam therapy for bacterial infections.

Authors:  D J Winston; R W Busuttil; T O Kurtz; L S Young
Journal:  Arch Intern Med       Date:  1981-11
View more
  1 in total

1.  Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.

Authors:  C Gimeno; D Navarro; F Savall; E Millás; M A Farga; J Garau; R Cisterna; J García-de-Lomas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.